Gleevec News
Most Popular Gleevec Story
AB soars on promising survival data from Phase II tumor study
Shares of Paris-based AB Science shot up yesterday after the drug developer reported strong efficacy results from a midstage study of its experimental drug for gastrointestinal tumors. The treatment, Read more...
Latest Headlines
- February 2, 2012
- December 4, 2007
- October 30, 2007
- October 9, 2007
- January 29, 2007
- January 29, 2007
- October 19, 2006
- July 23, 2006
- June 28, 2006
- June 4, 2006
- April 9, 2006
- March 27, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
